A dual diacylglycerol kinase (DGK) alpha/zeta inhibitor augments the activity of human tumor infiltrating lymphocytes in <i>in vivo</i> and <i>ex vivo</i> models.

Oncoimmunology · 2026 · PMC12758329 · PMID 41459935

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

We also found an increasing trend in normalized mRNA reads of CXCL11 (2.9-fold, Figure 6f ), CCL2 (2.2-fold, Figure 6g ) and IL-1B (2.1-fold, Figure 6h ).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

A dual diacylglycerol kinase (DGK) alpha/zeta inhibitor augments the activity of human tumor infiltrating lymphocytes in &lt;i&gt;in vivo&lt;/i&gt; and &lt;i&gt;ex vivo&lt;/i&gt; models.

The sentences

A dual diacylglycerol kinase (DGK) alpha/zeta inhibitor augments the activity of human tumor infiltrating lymphocytes in <i>in vivo</i> and <i>ex vivo</i> models.